{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:29:24Z","timestamp":1762100964917,"version":"build-2065373602"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.rdc.2009.06.005","type":"journal-article","created":{"date-parts":[[2009,7,31]],"date-time":"2009-07-31T12:59:38Z","timestamp":1249045178000},"page":"421-435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Neurophysiopathogenesis of Fibromyalgia Syndrome: A Unified Hypothesis"],"prefix":"10.1016","volume":"35","author":[{"given":"I. Jon","family":"Russell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2009.06.005_bib1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American College of Rheumatology 1990 criteria for the classification of fibromyalgia","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2009.06.005_bib2","first-page":"18","article-title":"Definitions and taxonomy of pain","volume":"vol. I","author":"Bonica","year":"1990"},{"key":"10.1016\/j.rdc.2009.06.005_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11916-003-0034-0","article-title":"Central sensitization in fibromyalgia and other musculoskeletal disorders","volume":"7","author":"Arendt-Nielsen","year":"2003","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.rdc.2009.06.005_bib4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0889-857X(02)00004-2","article-title":"Management of peripheral pain generators in fibromyalgia","volume":"28","author":"Borg-Stein","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.rdc.2009.06.005_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11926-002-0038-5","article-title":"Evidence of involvement of central neural mechanisms in generating fibromyalgia pain","volume":"4","author":"Staud","year":"2002","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"10.1016\/j.rdc.2009.06.005_bib6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jpain.2007.06.006","article-title":"Temporal summation of second pain and its maintenance are useful for characterizing widespread central sensitization of fibromyalgia patients","volume":"8","author":"Staud","year":"2007","journal-title":"J Pain"},{"key":"10.1016\/j.rdc.2009.06.005_bib7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0304-3959(00)00432-2","article-title":"Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome","volume":"91","author":"Staud","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.rdc.2009.06.005_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jpain.2005.01.357","article-title":"Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects","volume":"6","author":"Staud","year":"2005","journal-title":"J Pain"},{"key":"10.1016\/j.rdc.2009.06.005_bib9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.pain.2006.06.001","article-title":"Mechanisms underlying development of spatially distributed chronic pain (fibromyalgia)","volume":"124","author":"Vierck","year":"2006","journal-title":"Pain"},{"key":"10.1016\/j.rdc.2009.06.005_bib10","series-title":"Textbook of pain","first-page":"269","article-title":"Testing pain mechanisms in persons in pain","author":"Reading","year":"1989"},{"key":"10.1016\/j.rdc.2009.06.005_bib11","series-title":"Bonica's management of pain","first-page":"73","article-title":"Spinal mechanisms and their modulation","author":"Terman","year":"2001"},{"key":"10.1016\/j.rdc.2009.06.005_bib12","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1126\/science.1381521","article-title":"Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition","volume":"257","author":"Malmberg","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.rdc.2009.06.005_bib13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0022-3565(25)38933-0","article-title":"An antinociceptive effect of capsaicin in the adult mouse mediated by the NH2-terminus of substance P","volume":"268","author":"Mousseau","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.rdc.2009.06.005_bib14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/art.1780350509","article-title":"Cerebrospinal fluid biogenic amine metabolites in fibromyalgia\/fibrositis syndrome and rheumatoid arthritis","volume":"35","author":"Russell","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2009.06.005_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00000441-199806000-00006","article-title":"Advances in fibromyalgia: possible role for central neurochemicals","volume":"315","author":"Russell","year":"1998","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.rdc.2009.06.005_bib16","first-page":"1564","article-title":"Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia","volume":"26","author":"Giovengo","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2009.06.005_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3959(00)00284-0","article-title":"Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways","volume":"87","author":"Larson","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.rdc.2009.06.005_bib18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/art.23223","article-title":"Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia","volume":"58","author":"Harris","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2009.06.005_bib19","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","article-title":"A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia","volume":"9","author":"Arnold","year":"2008","journal-title":"J Pain"},{"key":"10.1016\/j.rdc.2009.06.005_bib20","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/art.20983","article-title":"Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial","volume":"52","author":"Crofford","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2009.06.005_bib21","first-page":"502","article-title":"A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia","volume":"35","author":"Mease","year":"2008","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2009.06.005_bib22","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1002\/art.20485","article-title":"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder","volume":"50","author":"Arnold","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2009.06.005_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pain.2005.06.031","article-title":"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder","volume":"119","author":"Arnold","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.rdc.2009.06.005_bib24","first-page":"1975","article-title":"Efficacy of milnacipran in patients with fibromyalgia","volume":"32","author":"Gendreau","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2009.06.005_bib25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.pain.2008.02.024","article-title":"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial","volume":"136","author":"Russell","year":"2008","journal-title":"Pain"},{"issue":"Suppl 1)","key":"10.1016\/j.rdc.2009.06.005_bib26","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/hup.622","article-title":"A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia","volume":"19","author":"Vitton","year":"2004","journal-title":"Hum Psychopharmacol"},{"issue":"9","key":"10.1016\/j.rdc.2009.06.005_bib27","first-page":"76","article-title":"Fibromyalgia syndrome: approach to management","volume":"13","author":"Russell","year":"2006","journal-title":"Prim Psychiatry"},{"issue":"2","key":"10.1016\/j.rdc.2009.06.005_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1300\/J094v01n02_03","article-title":"Prevalence of myofascial pain syndrome in fibromyalgia syndrome and regional pain syndrome: a comparative study","volume":"1","author":"Granges","year":"1993","journal-title":"J Musculoskel Pain"},{"key":"10.1016\/j.rdc.2009.06.005_bib29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11916-002-0048-z","article-title":"Myofascial pain syndrome and its suggested role in the pathogenesis and treatment of fibromyalgia syndrome","volume":"6","author":"Meyer","year":"2002","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.rdc.2009.06.005_bib30","first-page":"944","article-title":"The fibromyalgia and myofascial pain syndromes: a preliminary study of tender points and trigger points in persons with fibromyalgia, myofascial pain syndrome and no disease","volume":"19","author":"Wolfe","year":"1992","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2009.06.005_bib31","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/art.10225","article-title":"Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia","volume":"46","author":"Gracely","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2009.06.005_bib32","series-title":"Wall and Melzack's textbook of pain","article-title":"Muscle and fibromyalgia syndrome","author":"Russell","year":"2005"},{"key":"10.1016\/j.rdc.2009.06.005_bib33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.amjmed.2005.10.051","article-title":"Insomnia in the elderly: cause, approach, and treatment","volume":"119","author":"Kamel","year":"2006","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.rdc.2009.06.005_bib34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/sleep\/30.4.494","article-title":"The effects of sleep deprivation on pain inhibition and spontaneous pain in women","volume":"30","author":"Smith","year":"2007","journal-title":"Sleep"},{"issue":"9","key":"10.1016\/j.rdc.2009.06.005_bib35","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/1529-0131(200109)44:9<2125::AID-ART365>3.0.CO;2-1","article-title":"Cognitive function in fibromyalgia patients","volume":"44","author":"Park","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2009.06.005_bib36","first-page":"2014","article-title":"Sleep, daytime symptoms, and cognitive performance in patients with fibromyalgia","volume":"24","author":"Cote","year":"1997","journal-title":"J Rheumatol"},{"issue":"15","key":"10.1016\/j.rdc.2009.06.005_bib37","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1523\/JNEUROSCI.0098-07.2007","article-title":"Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain?","volume":"27","author":"Kuchinad","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.rdc.2009.06.005_bib38","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1212\/01.wnl.0000183067.94400.80","article-title":"Gray matter decrease in patients with chronic tension type headache","volume":"65","author":"Schmidt-Wilcke","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.rdc.2009.06.005_bib39","doi-asserted-by":"crossref","first-page":"10410","DOI":"10.1523\/JNEUROSCI.2541-04.2004","article-title":"Chronic back pain is associated with decreased prefrontal and thalamic gray matter density","volume":"24","author":"Apkarian","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.rdc.2009.06.005_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pain.2006.05.004","article-title":"Affective components and intensity of pain correlate with structural differences in gray matter in chronic back pain patients","volume":"125","author":"Schmidt-Wilcke","year":"2006","journal-title":"Pain"},{"key":"10.1016\/j.rdc.2009.06.005_bib41","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1523\/JNEUROSCI.17-14-05503.1997","article-title":"Effects of regional anesthesia on phantom limb pain are mirrored in changes in cortical reorganization","volume":"17","author":"Birbaumer","year":"1997","journal-title":"J Neurosci"},{"key":"10.1016\/j.rdc.2009.06.005_bib42","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1586\/14737175.8.5.809","article-title":"Maladaptive plasticity, memory for pain and phantom limb pain: review and suggestions for new therapies","volume":"8","author":"Flor","year":"2008","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.rdc.2009.06.005_bib43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0304-3959(00)00385-7","article-title":"The effect of opioids on phantom limb pain and cortical reorganization","volume":"90","author":"Huse","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.rdc.2009.06.005_bib44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/01.rmr.0000245457.98029.e1","article-title":"Comparisons between Alzheimer disease, frontotemporal lobar degeneration, and normal aging with brain mapping","volume":"16","author":"Whitwell","year":"2005","journal-title":"Top Magn Reson Imaging"},{"key":"10.1016\/j.rdc.2009.06.005_bib45","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.pnpbp.2005.06.026","article-title":"Homocysteine and brain atrophy","volume":"29","author":"Sachdev","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.rdc.2009.06.005_bib46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/03009749709105320","article-title":"Increased concentrations of homocysteine in the cerebrospinal fluid in patients with fibromyalgia and chronic fatigue syndrome","volume":"26","author":"Regland","year":"1997","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.rdc.2009.06.005_bib47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1179\/135100006X116628","article-title":"Total antioxidant capacity and the severity of the pain in patients with fibromyalgia","volume":"11","author":"Altindag","year":"2006","journal-title":"Redox Rep"},{"issue":"3","key":"10.1016\/j.rdc.2009.06.005_bib48","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1179\/rer.2007.12.3.134","article-title":"Paraoxonase and arylesterase activities in fibromyalgia","volume":"12","author":"Altindag","year":"2007","journal-title":"Redox Rep"},{"key":"10.1016\/j.rdc.2009.06.005_bib49","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00296-003-0427-8","article-title":"Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder?","volume":"25","author":"Bagis","year":"2005","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.rdc.2009.06.005_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1300\/J094v05n04_02","article-title":"Reactive oxygen species, antioxidant status and fibromyalgia","volume":"5","author":"Eisinger","year":"1997","journal-title":"J Musculoskel Pain"},{"key":"10.1016\/j.rdc.2009.06.005_bib51","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1212\/WNL.54.10.2009","article-title":"Increased CSF levels of nerve growth factor in patients with Alzheimer's disease","volume":"54","author":"Hock","year":"2000","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.rdc.2009.06.005_bib52","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1055\/s-2007-973712","article-title":"Elevated nerve growth factor levels in cerebrospinal fluid associated with progressive cortical atrophy","volume":"28","author":"Suzaki","year":"1997","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.rdc.2009.06.005_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0304-3940(92)90762-V","article-title":"Elevated nerve growth factor in the spinal fluid of patients with multiple sclerosis during exacerbations","volume":"147","author":"Bracci-Laudiero","year":"1992","journal-title":"Neurosci Lett"},{"issue":"2","key":"10.1016\/j.rdc.2009.06.005_bib54","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1381612013398383","article-title":"Nerve growth factor in neurological and non-neurological diseases: basic findings and emerging pharmacological prospectives","volume":"7","author":"Aloe","year":"2001","journal-title":"Curr Pharm Des"},{"issue":"6","key":"10.1016\/j.rdc.2009.06.005_bib55","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1097\/00000542-200312000-00024","article-title":"A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor\u2013induced hyperalgesia","volume":"99","author":"Farquhar-Smith","year":"2009","journal-title":"Anesthesiology"},{"issue":"7","key":"10.1016\/j.rdc.2009.06.005_bib56","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/rheumatology\/40.7.743","article-title":"Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study","volume":"40","author":"Wallace","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2009.06.005_bib57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/287158a0","article-title":"Requirement of nerve growth factor for the development of substance P containing neurons","volume":"287","author":"Otten","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.rdc.2009.06.005_bib58","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1523\/JNEUROSCI.01-11-01304.1981","article-title":"Use of an experimental autoimmune model to define nerve growth factor dependency of peripheral and central substance P\u2013containing neurons in the rat","volume":"1","author":"Ross","year":"1981","journal-title":"J Neurosci"},{"key":"10.1016\/j.rdc.2009.06.005_bib59","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0306-4522(94)90366-2","article-title":"Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity","volume":"62","author":"Woolf","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.rdc.2009.06.005_bib60","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bbr.2005.09.008","article-title":"Sleep disturbance induced by substance P in mice","volume":"167","author":"Andersen","year":"2006","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.rdc.2009.06.005_bib61","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/0006-3223(85)90193-3","article-title":"CSF substance P in affective disorders","volume":"20","author":"Berrettini","year":"1985","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.rdc.2009.06.005_bib62","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/15622970309167952","article-title":"Substance P and substance P receptor antagonists in the pathogenesis and treatment of affective disorders","volume":"4","author":"Herpter","year":"2003","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.rdc.2009.06.005_bib63","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1126\/science.281.5383.1640","article-title":"Distinct mechanism for antidepressant activity by blockade of central substance P receptors","volume":"281","author":"Kramer","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.rdc.2009.06.005_bib64","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(05)61444-4","article-title":"Substance P antagonists: a new treatment for depression?","volume":"352","author":"Nutt","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2009.06.005_bib65","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0889-857X(01)00006-0","article-title":"The promise of substance P inhibitors in fibromyalgia","volume":"28","author":"Russell","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.rdc.2009.06.005_bib66","first-page":"733","article-title":"In vivo immunomodulation by the neuropeptide substance P","volume":"63","author":"Scicchitano","year":"1988","journal-title":"Immunology"},{"key":"10.1016\/j.rdc.2009.06.005_bib67","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/10253890009001125","article-title":"Substance P is involved in terminating the hypothalamo- pituitary-adrenal axis response to acute stress through centrally located neurokinin-1 receptors","volume":"3","author":"Jessop","year":"2000","journal-title":"Stress"},{"key":"10.1016\/j.rdc.2009.06.005_bib68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2826.1993.tb00368.x","article-title":"Substance P inhibits the release of anterior pituitary adrenocorticotrophin via a central mechanism involving corticotrophin-releasing factor containing neurons in the hypothalamic paraventricular nucleus","volume":"5","author":"Larsen","year":"1993","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.rdc.2009.06.005_bib69","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1568007043482516","article-title":"Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms?","volume":"3","author":"Adell","year":"2004","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1016\/j.rdc.2009.06.005_bib70","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-2710.1999.00257.x","article-title":"Substance P antagonists: the next breakthrough in treating depression?","volume":"24","author":"Baby","year":"1999","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.rdc.2009.06.005_bib71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.1780380104","article-title":"The prevalence and characteristics of fibromyalgia in the general population","volume":"38","author":"Wolfe","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2009.06.005_bib72","first-page":"1570","article-title":"The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario","volume":"26","author":"White","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2009.06.005_bib73","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cpr.2005.04.008","article-title":"Treatment of insomnia in older adults","volume":"25","author":"Naua","year":"2005","journal-title":"Clin Psychol Rev"},{"issue":"5","key":"10.1016\/j.rdc.2009.06.005_bib74","first-page":"468","article-title":"Genetic linkage of fibromyalgia to the serotonin receptor 2A region on chromosome 13 and the HLA region on chromosome 6","volume":"72","author":"Dudek","year":"2003","journal-title":"Am J Hum Genet"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X0900043X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X0900043X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:09:09Z","timestamp":1760180949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X0900043X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0889857X0900043X"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2009.06.005","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurophysiopathogenesis of Fibromyalgia Syndrome: A Unified Hypothesis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2009.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}